Abstract: A methicillin-resistant Staphylococcus aureus (MRSA) strain was recovered in a neonatal intensive care unit from 3 blood and 3 sputum specimens with antibiotic susceptibility profile characteristic of community-acquired MRSA. Epidemiologic survey resulted in isolation of an identical strain from the nares of one nurse. All isolates carried a new SCCmec type IIIA variant. Treatment of the nurse with topical mupirocin resulted in cessation of the outbreak. S taphylococcus aureus is the second most common pathogen causing late-onset septicemia in neonatal intensive care units (NICUs) and methicillin-resistant S. aureus (MRSA) strains have become a well-documented epidemiologic problem. Community-acquired MRSA (CA-MRSA), which has emerged as a cause of infections outside of healthcare settings, differs from health care-associated MRSA (HA-MRSA) by its susceptibility to numerous antimicrobial agents and because it carries the staphylococcal cassette chromosome mec (SCCmec) type IV rather than type I, II or III.
1
Community-acquired MRSA (CA-MRSA), which has emerged as a cause of infections outside of healthcare settings, differs from health care-associated MRSA (HA-MRSA) by its susceptibility to numerous antimicrobial agents and because it carries the staphylococcal cassette chromosome mec (SCCmec) type IV rather than type I, II or III. 2 CA-MRSA has been also isolated from patients in NICUs [3] [4] [5] ; however, the way of its introduction into the unit has generally remained unknown. We report a nosocomial MRSA outbreak in the NICU by a nonmultidrug-resistant (non-MDR) strain that carries a rare SCCmec type IIIA variant-1 recently described in Taiwan. 6 The same strain was isolated from the nares of a personnel member.
We believe that our report is the first published description of the introduction of this strain into the nursery and may shed light on the introduction of community-acquired strains into the NICU.
PATIENTS AND METHODS
The Outbreak. During July to September 2004, three cases of S. aureus bacteremia were recorded in the NICU of Wolfson Medical Center, Holon, Israel. All isolates had the same antibiotic susceptibility pattern compatible with CA-MRSA: strains were susceptible to vancomycin, erythromycin, clindamycin and trimethoprim-sulfamethoxazole but resistant to gentamicin and ofloxacin.
In addition, S. aureus isolates with the same susceptibility pattern were recovered from three sputum specimens (one obtained from a patient with S. aureus bacteremia and two from two other infants) while these infants were mechanically ventilated. All isolates except for the blood sample of the first patient were collected during a 1-week period, whereas patient no. 1's sample was collected 5 weeks before the other isolates.
The neonates with S. aureus bacteremia were treated with vancomycin with favorable results. The two patients with sputumpositive culture only were not specifically treated for the S. aureus carriage. In light of these findings, an epidemiologic investigation was undertaken.
Epidemiologic Investigations
Surveillance Cultures. Cultures were taken from 33 members, including nonmedical personnel, nurses and physicians. Cultures were also obtained from neonates hospitalized at the NICU. The cultures were obtained from nail beds and nostrils. Antimicrobial Susceptibility Testing. Antibiotic susceptibility of all MRSA isolates was determined using the VITEK-2 system (bioMerieux, Hazelwood, MO). Oxacillin resistance was verified on MRSA screening agar plates (HY-PD MRSA plates; Hy-Labs, Israel). Phage Typing. Phage typing of the isolates was performed using the technique of Blair and Williams 7 with phages issued by the International Reference Laboratory, Colindale, U.K. Genetic Typing by Pulsed-Field Gel Electrophoresis. Chromosomal DNA was prepared and cleaved with SmaI endonuclease (New England Biolabs, Boston, MA) as previously described. 8 Agarose plugs were loaded onto a 1% agarose gel (BMA Products, Rockland, ME), prepared and run in 0.5ϫ Tris-Borate-EDTA buffer on a CHEF-DR III apparatus (Bio-Rad Laboratories, Inc., Hercules, CA). Electrophoresis was performed at 6 V/cm and 14°C. The running time was 23 hours with pulse times ranging from 5 to 40 seconds. Gels were stained with ethidium bromide, destained in distilled water and photographed in ultraviolet light using a Bio-Rad GelDoc camera (Bio-Rad). The genetic relatedness between all clinical isolates was determined by comparing between the DNA macrorestriction patterns. Staphylococcal Chromosomal Cassette (SCCmec) Typing. SCCmec typing was performed according to Oliviera and de Lencastre using described primers for 7 different loci (loci A-H). 9 Crude bacterial cell lysates were used as DNA templates. The polymerase chain reaction (PCR) reaction conditions were as following: 15 minutes at 95°C, 30 cycles of 1 minute at 94°C, 2 minutes at 62°C, 3 minutes at 72°C and 10 minutes at 72°C. PCR reactions were performed with Hot-Star TaqDNA polymerase (Qiagen, Hilden, Germany) according to the manufacturer's instructions. MRSA strains with known SCCmec type were used as control strains in the multiplex PCR reactions and were electrophoresed in parallel to the studied outbreak strains. SCCmec type I, II and IV controls were isolated from Tel Aviv Medical Center and SCCmec type III (strain HT 2004 0858) was provided as a gift from Jerome Etienne Laboratory, Lyon, France.
RESULTS
Surveillance Cultures. Thirty-three staff members were screened. Eight (24%) carried S. aureus. Seven were methicillin-sensitive S. aureus (MSSA) isolates and one was a MRSA recovered from a nurse nostril. This MRSA strain had an identical antibiotic susceptibility pattern as the clinical strains isolated from blood and sputum of the previously described neonates.
Six MRSA isolates were characterized: 2 isolates from the blood, 3 sputum isolates and one isolate from the nurse. Patient no. 1 isolates were not kept in the laboratory and we could not further type it. All isolates had the same phage typing and were found to be sensitive to the following phages: 29, 52, 80, 90, 92 (88, 89). Pulsed-field gel electrophoresis (PFGE) identified a single identical outbreak strain. All non-MDR MRSA were found to carry SCCmec type IIIA variant, lacking the 209bp amplicon of truncated mecI gene (Fig. 1) . All staff
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Questioning of the nurse who carried MRSA strain revealed that she begun her work in the NICU approximately 3 weeks before recovery of the first MRSA isolate. Cultures taken her family members did not grow out MRSA isolates.
DISCUSSION
In the past few years, there have been a dramatic increase in CA-MRSA infections in patients who have not had any risk factors for MRSA infection. It seems that CA-MRSA strains are epidemiologically and clonally unrelated to hospital-acquired strains. 10 SCCmec types I, II and III are common in healthcare-associated MRSA, which are typically multidrug-resistant. Type IV SCCmec is found in CA-MRSA strains, which are usually resistant to beta-lactams and macrolides but susceptible to clindamycin and trimethoprimsulfamethoxazole. Recently, CA-MRSA strains have emerged as a significant cause of disseminated infection in the NICU with substantial morbidity and mortality.
3 CA-MRSA outbreaks in the NICU have also been recently reported 4, 5 ; however, the source of the outbreak and mechanism of transmission in the previously mentioned reports were not evident.
In our report, all of the isolations were in a timeframe of a less than 2 months. The laboratory investigations that included phage typing, PFGE, and genetic assessment demonstrated that all MRSA isolates collected during this survey from the patients and from the staff member were identical. We could not recover the strain isolated from patient no. 1 and therefore could not include that strain in the laboratory studies. However, the temporal occurrence of cases and antibiotic susceptibility pattern of the strain in patient no. 1 was identical to that of other MRSA strains isolated at the NICU, which all support that the MRSA infection of patient no. 1 was part of the outbreak.
Genetic typing revealed that the isolates carried SCCmec type IIIA variant. This variant was recently reported in Taiwan and was isolated from the community and also from healthcare facilities; therefore, it is difficult to determine whether this strain belongs to CA-MRSA lineage or it is a health care-associated. The antibiotic susceptibility pattern of the outbreak strain isolated from our unit may suggest that this strain was originated from the community; however, additional epidemiologic data are necessary for better classification of this strain.
Horizontal transmission of S. aureus from colonized visitors or from infants to infants in the NICU could theoretically have been a mode of transmission in our patients. However, this mode of transmission seems to be less likely and transmission through a staff member seems to be more reasonable for several reasons. First, the cluster of cases was first documented soon after the colonized nurse had started working in the NICU. Second, after treating the nurse, there were no more cases of MRSA infections or colonization.
We believe that the investigation and intervention undertaken prevented further transmission and additional invasive MRSA infections in the NICU. Our report suggests that isolation of CA-MRSA or CA-MRSA-like strain in the NICU should prompt an epidemiologic survey to look for the potential source because such isolation indicates introduction of the bacteria from external source such as a staff member.
A periodically routine survey for ICU personnel members as a measure of infection prevention and control may also prevent similar outbreaks. P neumonia remains a cause of considerable morbidity in childhood with either sustained or increased rates of complicated pneumonia, including empyema, being reported. [1] [2] [3] During the winter of 2003-2004, a marked increase in the number of children presenting with empyema at our institution, a tertiary referral facility, was observed compared with the previous year. For the 12 months from August 1, 2002, 10 children were coded as having a primary diagnosis of empyema, whereas 31 were so coded for the same period in [2003] [2004] . Although this may have reflected unknown changes in practice, there were no internal system changes to suggest that this reflected variation in coding procedures rather than in morbidity and no changes in service delivery or referral patterns were recorded.
Data from the United States has confirmed that the conjugate pneumococcal vaccine has had a significant impact on invasive pneumococcal infection 4 with evidence of herd immunity in unimmunized age groups. However, severe cases of disease caused by serotypes not included in the current 7-valent conjugate vaccine continue to occur as documented by Byington et al, 5 who also noted an increase in childhood empyema coincident with the introduction of PCV7.
In view of the apparent increased rates of complicated pneumonia and the expected imminent introduction of pneumococcal conjugate vaccine into the U.K. primary schedule, a detailed examination of the pathology of all cases presenting to our hospital with complex effusion or for surgical drainage after failure of conservative treatment was undertaken. Enhanced diagnostic procedures were used to determine the proportion of cases in which the etiology was Streptococcus pneumoniae and, in these cases, the proportions caused by serotypes included in the 7-valent conjugate vaccine.
MATERIALS AND METHODS
During the 12 months from August 2003, all empyema cases were prospectively ascertained in our secondary/tertiary pediatric center by daily review of admissions. All cases were confirmed by chest radiograph and ultrasound examination and, from the history, were attributable to community-acquired infection in previously well children.
Informed signed consent was obtained to record clinical details and analyze empyema fluid (pus in all cases) for evidence of pneumococcal infection, as detailed subsequently. Parents were also interviewed to ascertain recent antibiotic use. The study was reviewed and approved by the institutional ethics committee.
All samples were subjected to pneumococcal capsular polysaccharide enzyme-linked immunosorbent assay (ELISA) (PCPE) for 13 serotypes and C polysaccharide ELISA (CPE) analysis. All ELISAs were solid-phase assays in which antigen was captured by polyclonal rabbit group or C polysaccharide-specific antiserum (Statens Serum Institut, Denmark) and mouse monoclonal antibodies (donated by Wyeth, NY) were used to detect captured antigen as previously described. 3, 6, 7 
RESULTS
Of 37 eligible cases ascertained, we obtained consent from 34 children and/or their parents for inclusion in the study. The majority of the children (28 of 34) were transferred from their local hospitals for surgical review and pleural drainage. The median age was 6.3 years (range ϭ 0.8 -14.8 years) on admission; 12 were girls, 2 of whom were siblings presenting during the same week (case nos. 13 and 14). Another child was treated for empyema at the same time as his mother presented with community-acquired pneumonia and pleural effusion.
Although cases presented throughout the year, 26 (70%) were recruited during the 6 months from November to April.
In 5 children, no pleural empyema fluid was available for ELISA analysis. Of these 5, positive nonpneumococcal empyema fluid cultures were obtained in 2 (one Staphylococcus aureus and one group A Streptococcus), Gram-positive cocci were seen, but cultures were negative in a third and all investigations, including routine empyema fluid culture, were negative in 2. Of the remaining 29 empyema fluid samples, 26 were positive for pneumococcus by PCPE; 18 serotype 1, one serotype 7F, 2 serotype 3, 3 serotype 4, one serotype 9V and one for both serotypes 4 and 23F. Of the 3 PCPE-negative cases, one was CPE positive, suggesting pneumo-
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Childhood Empyema coccal infection with a serotype not in the PCPE panel and 2 had positive empyema fluid cultures for group A Streptococcus. Positive cultures were also obtained for 8 of the children with positive PCPE results; 2 from empyema fluid (S. pneumoniae and coagulasenegative Staphylococcus spp., respectively) and 6 from blood (all S. pneumoniae, one also H. influenzae).
DISCUSSION
More children were identified by active prospective surveillance than by retrospective review of International Classification of Diseases, 10th Revision codings, but most were identified by both approaches, suggesting that coding is broadly reliable in our center. The apparent increase in the number of cases of empyema presenting at this hospital during the winter of 2003-2004 could reflect either a rise in incidence or changes in referral patterns, although there have been no significant service changes to suggest the latter.
Lack of culture-proven diagnosis remains common in pediatric empyema. 2, 7 Our data show that in children with this condition in whom all cultures are negative, the causative organism is usually the pneumococcus and most often serotype 1. Microbiologic proof is valuable to the clinician in determining the optimal antibiotic regimen. Our data, the largest series published using diagnosis by pneumococcal antigen analysis (PCPE and PCE) of empyema fluid, strongly suggests that this is a sensitive and clinically useful diagnostic test in this setting.
Antigen analysis resulted in a microbiologic diagnosis for all 29 cases when fluid was available and a serotype assigned in all but one pneumococcal infection.
A predominance of serotype 1 among cases of pneumococcal empyema has recently been reported in the United Kingdom 3,7 and the United States 2 and is reconfirmed in this study. This contrasts with the low reported proportion of cases of pneumococcal invasive disease overall 8 and very low rates of colonization 9 caused by this serotype. The reason for this high invasive potential and predilection for the pleural space is unknown. Certainly, the relative importance of this serotype in empyema undermines the notion that serotypes not included in the current conjugate vaccine are not only rarer, but also less virulent. 10 Serotype 1 was more prevalent in the early 20th century both in Northern Europe and North America 11, 12 and there is no reason, in principle, why this pattern should not recur in the future based on our observations and those of Byington et al. 5 Immunization with the 7-valent pneumococcal conjugate vaccine significantly reduces invasive pneumococcal disease in children 4 ; however, a vaccine that includes serotype 1 would be needed to reduce the morbidity reported here. Further studies to characterize serotype 1 isolates could help elucidate their apparent predilection to cause pleural empyema in our population. C ongenital hydrocephalus is an uncommon condition with a prevalence of 0.3 to 2.5 per 1000 live births 1 and is frequently idiopathic. Congenital infection with Toxoplasma gondii and rarely cytomegalovirus are recognized causes of hydrocephalus. Noninfectious causes include myelomeningocele, Dandy-Walker malformation, aqueductal stenosis and genetic and neoplastic conditions. Lymphocytic choriomeningitis virus (LCMV) has recently been recognized as a cause of neonatal hydrocephalus. In utero infection with this arenavirus can also cause chorioretinitis and fetal death. We report a case of an infant with congenital hydrocephalus, initially attributed to idiopathic aqueductal stenosis, who was eventually diagnosed with congenital LCMV infection. It is the first report of LCMV isolation from the cerebrospinal fluid of a congenitally infected infant.
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The Pediatric Infectious Disease Journal • Volume 25, Number 6, June 2006 CASE REPORT A 15 day-old boy with a history of congenital hydrocephalus was admitted to the hospital with a 12-hour history of fever. He had been discharged from the neonatal intensive care unit (NICU) 2 days earlier after a 13-day hospital stay for management of congenital hydrocephalus. He had no rhinorrhea, cough, rash or lethargy. He had been eating well and had no vomiting or diarrhea before admission.
The patient's mother presented to Cedars-Sinai Medical Center for prenatal care at 32 weeks gestation and congenital hydrocephalus was subsequently diagnosed by prenatal ultrasound. The infant was born by cesarean section without complication at 36 weeks gestation. The patient's mother received routine prenatal care and had no history of fever, chorioamnionitis or travel. There was no known prenatal animal exposure. Maternal serologies were negative for toxoplasmosis, cytomegalovirus, human immunodeficiency virus and syphilis. She was hepatitis B surface antigen-negative. Laboratory studies on the infant's cerebrospinal fluid (CSF) initially revealed 1330/mm 3 red blood cells and 4/mm 3 white blood cells with a glucose of 29 mg/dL, a protein of 149 mg/dL and negative bacteriologic culture. The infant had a ventriculoperitoneal (VP) shunt placed on the fourth day of life. Left ear deafness was detected on routine hearing screen before discharge from the NICU on day of life 13.
On admission at 15 days of age, vital signs included temperature of 101.8°F, pulse of 158 beats/min, blood pressure of 74/60 mm Hg, respiratory rate of 44 breaths/min and pulse oximetry 99%. His growth indices included weight 3.23 kg (25%) (birth weight 3.34 kg), length 45 cm (5%) and head circumference 37 cm (50%) (birth head circumference 40.5 cm, Ͼ95%). He was awake and crying but consolable during examination. The anterior fontanelle was soft and flat. The VP shunt site was soft and without erythema. The remainder of the examinations, including neurologic examination, was unremarkable. He moved all extremities with normal tone and strength. He had a symmetric Moro reflex, normal suck and grasp reflexes.
A head computed tomography scan on admission revealed massive dilatation of the lateral ventricles with a VP shunt in place. CSF obtained from the VP shunt reservoir showed 345/mm 3 white blood cells (segmented neutrophils 22%, lymphocytes 23%, monocytes 23%), 85/mm 3 red blood cells, protein 587 mg/dl, glucose 18 mg/dL, Gram-stain: 3ϩ neutrophils, 3ϩ monocytes and no visible bacteria. A complete blood count showed a white blood cell count of 13,900/mm 3 (segmented neutrophils 36%, lymphocytes 31%, band forms 16%, monocytes 17%), hemoglobin of 10.8 g/dL and platelet count of 360,000/mm 3 . Electrolytes were normal. A routine urinalysis was negative.
The infant was empirically treated with vancomycin and cefotaxime. CSF culture from admission showed no bacterial growth. On the third hospital day, the VP shunt was removed and a ventricular reservoir was placed. CSF cultures from daily reservoir taps were negative for bacteria and viruses. A urine viral culture was negative for cytomegalovirus and serology for toxoplasmosis was negative. On the sixth day of hospitalization, an ophthalmologic examination revealed bilateral chorioretinitis.
Serology (indirect fluorescent antibody test) for LCMV was positive with an IgG titer of 1:256. This was confirmed by enzymelinked immunosorbent assay (ELISA) on the serum and CSF of the patient as well as maternal serum at the Centers for Disease Control and Prevention. The patient's serum IgG and IgM titers were 1:6400 and 1:400, respectively, and his CSF IgG and IgM titers were 1:1280 and 1:320, respectively. The patient's mother's serum was also positive for LCMV antibodies with IgG and IgM ELISA titers of 1:6400 and 1:400, respectively. Virus isolation attempts in Vero E6 cells from the CSF of the patient were positive. Reverse transcription-polymerase chain reaction (RT-PCR) and sequencing using previously described primers identified the virus isolates as a unique strain of LCMV. 2 This is the first report of isolation of LCMV from the CSF of a congenitally infected child. Further review of the maternal exposure history revealed extensive occupational exposure to mice and rats. The patient's mother worked in the garment district and her job responsibilities included cleaning up rodent droppings from the showroom. The county health department found no evidence of rodent infestation in the patient's home.
DISCUSSION
LCMV is a single-stranded RNA arbovirus that was first isolated in 1933. 3 The natural reservoir of LCMV is the house mouse, Mus musculus; however, pet hamsters and guinea pigs have also been responsible for human infection. Rodents can be chronically and asymptomatically infected with LCMV, which is persistently shed in urine, feces and saliva. 4 LCMV is transplacentally transmitted in rodents. 5 LCMV, associated with its rodent reservoir, has a worldwide distribution. 6 Previous studies have found an LCMV antibody prevalence of 9% in house mice in the eastern United States. 6 Human disease follows inhalation or direct exposure of infected mouse excretions. There is no evidence of person-toperson spread other than maternal-fetal transmission and recent transplant-associated cases. 7, 8 The first case of congenital LCMV was described in England in 1955; however, it was not recognized in the United States until 1992. 9 Pathogenesis of congenital LCMV is thought to occur by transplacental passage of the virus during maternal viremia 10 into the fetal central nervous system through the choroid plexus. Replication occurs in the cells of the ependyma and periventricular germinal matrix, resulting in necrotizing ependymitis and inflammation. This can result in hydrocephalus and intracranial destruction. 11 Fetal loss has been reported from infections occurring during the first trimester, 10, 12 whereas infection occurring later in pregnancy may result in hydrocephalus and chorioretinitis. 11 As development progresses in a patient with congenital LCMV infection, neurologic sequelae become more apparent and include cerebral palsy, mental retardation and seizures, reported to occur in more than 80% of surviving infants. 4, 10 Approximately 35% of infants die of complications of congenital LCMV infection.
Congenital infection with LCMV closely resembles in utero infection with other infectious agents such as T. gondii and occasionally cytomegalovirus. Hydrocephalus and chorioretinitis are characteristic features of toxoplasmosis and LCMV infections. Cytomegalovirus and T. gondii have a predilection for the macula. 9 Eye findings consistent with LCMV are varied and chorioretinal scars were seen in the periphery of the retina in 71% of cases in a study by Barton and Mets. 10 Many tests have been used for the diagnosis of LCMV. Complement fixation tests have been replaced by more sensitive indirect fluorescent antibody (IFA) tests detecting both IgM and IgG. However, no serologic assay is flawless. The IFA can detect antibody within a few days of clinical symptoms, whereas the compliment fixation tests detect antibody weeks after clinical presentation. ELISA tests have become the primary serologic assay, although not routinely done and more recently, RT-PCR is being used for the detection of viral RNA. 13 Evaluation of infants for intrauterine infection should be done as soon after birth as practical and parallel testing of the mother for antibody is useful. Treatment of LCMV infection is supportive. There is no specific treatment; however, ribavirin has in vitro antiviral activity against LCMV. 4 Infection with LCMV in children and adults is typically mild and short-lived, but maternal infection during pregnancy can lead to L inezolid (LZD), the first approved oxazolidine antibiotic, has broad activity against Gram-positive bacteria and is used predominantly to treat methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and coagulasenegative staphylococcal infections. LZD binds to domain V of the 23S rRNA of the 50S ribosomal subunit and inhibits the initiation of protein synthesis. 1 Although resistance to LZD remains rare, mutations conferring resistance have been found on the 23S rRNA genes. Resistance has been reported primarily in enterococci, but also in S. aureus and other Gram-positive bacteria.
2-4
We report 2 pediatric patients (siblings) with hyper-IgE syndrome (HIES, or Job syndrome) who developed LZD-resistant MRSA. HIES is a rare primary immunodeficiency characterized by recurrent infections, eczema, elevated serum IgE levels and a variety of connective tissue and skeletal abnormalities. Patients with HIES typically require long-term suppressive antibiotic therapy to control skin disease and prevent infections. These 2 patients were treated intermittently with extended courses of once-daily low-dose LZD to suppress staphylococcal skin and sinus disease. We analyzed the molecular epidemiology of 12 clinical isolates of S. aureus from these patients obtained over 4 years and identified the underlying mutation of the 2 LZD-resistant MRSA strains.
CASE HISTORIES
Patient no. 1 was a 16-year-old with HIES characterized by chronic sinusitis and otitis media, eczema, recurrent skin infections, eosinophilic esophagitis and elevated serum IgE. In November 2001, as a result of worsening of MRSA-related skin disease, intravenous vancomycin was started; however, because of intolerance, therapy was changed to oral LZD (15 mg/kg per day divided twice daily) after 1 week. She remained on LZD therapy until May 2003 with worsening of skin disease during trials off therapy. Her dose was then decreased to 300 mg daily (5 mg/kg per day) for suppressive therapy along with 50 mg pyridoxine daily. She remained on this regimen until March 2005 when she presented with mild worsening of her skin disease and sinusitis. Clindamycin therapy was initiated and a nasal culture for S. aureus revealed LZD-resistant MRSA (LZD minimum inhibitory concentration ͓MIC͔ ϭ 32 g/mL). LZD therapy was discontinued with gradual worsening of her skin disease. Two months later, an LZDsusceptible MRSA isolate was recovered.
Patient no. 2 was an 11-year-old sibling of patient no. 1 who also had HIES characterized by eczema, recurrent sinusitis and otitis media, osteopenia, a right patellar fracture and an elevated serum IgE. In November 2001, she was treated with intravenous vancomycin for MRSA exacerbation of her skin disease; however, because of intolerance, therapy was changed to oral LZD (22 mg/kg per day divided twice daily). Her symptoms resolved and she was maintained on LZD therapy for 9 months for control of skin disease. In July 2004, LZD therapy (17.5 mg/kg per day divided twice daily)
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was initiated for MRSA exacerbation of her skin disease. After 2 weeks of therapy, 300 mg LZD per day (9 mg/kg per day once daily) was given along with 50 mg pyridoxine daily. In March 2005, she presented with a mild eczema flare, worsening of sinusitis and cough. Clindamycin therapy was started for sinusitis and a skin drainage culture was positive for LZD-resistant MRSA (MIC ϭ 64 g/mL). LZD therapy was discontinued and 2 months later, an LZD-susceptible MRSA was recovered.
MICROBIOLOGIC METHODS Twelve S. aureus isolates (10 MRSA) were obtained between 2001 and 2005 from the 2 sisters. Susceptibility testing to LZD was performed using the MicroScan microdilution method and E-test agar diffusion method. Six of these strains, collected before and after failed LZD therapy, were also tested using the reference macrodilution method. All strains were characterized by the Diversilab Staphylococcus rep-PCR kit (Bacterial Barcodes Inc., Houston, TX). Clonal relationships of the 10 MRSA strains were further evaluated by PFGE of SmaI and of EagI macrorestricted genomic DNA. To identify possible mutations, domain V of the 23S rRNA gene was amplified and sequenced from 6 MRSA strains from before and after failed LZD therapy using primers targeting conserved regions.
5

RESULTS
Susceptibility testing showed that the MRSA isolates from both patients in March 2005 after clinical worsening were highly LZD-resistant, with MICs of 32 g/mL (patient no. 1) and 64 g/mL (patient no. 2) by the reference macrodilution method. Resistance to LZD was also confirmed by E-test. All other isolates, as well as those isolated in May 2005 after LZD discontinuation, were LZDsusceptible (Table 1) .
Rep-PCR analysis sorted the 12 strains of S. aureus into a cluster of 10 indistinguishable strains of MRSA and 2 unrelated MSSA strains. PFGE of the 10 MRSA isolates further separated the cluster into a major group containing 5 indistinguishable isolates (composite type C) and 3 other related subtypes, C-1 to C-3. LZD-resistant strains were classified as distinguishable composite subtypes C-2 and C-3 (Table 1 and Figs. 1 and 2 of the online version of the article).
Amplification and sequencing of the V domain of the 23S rRNA gene identified the G2576T mutation in both LZD-resistant isolates. Susceptible strains did not carry this mutation, including the strains obtained after LZD discontinuation. DISCUSSION LZD resistance remains rare. In recent surveillance programs, LZD resistance rates were less than 0.1%. 3, 4 Resistance has been typically associated with prolonged LZD courses, indwelling devices and undrained abscesses and has occurred most frequently in enterococci. 6 Since the first report in 2001, 7 there have been few clinical reports of LZD-resistant S. aureus: in a patient treated for empyema, a patient with cystic fibrosis with recurrent MRSA infections, a patient with ventilator-associated pneumonia and a patient with an endovascular infection. 2 Unlike our patients, these patients were adults and were treated for acute or recurrent infections and not with prolonged suppressive LZD courses.
The development of resistance in these 2 sisters is likely a result of prolonged administration of low-dose LZD dosages for suppression of HIES-associated MRSA skin disease and infections. Rep-PCR rapidly typed and identified 10 related MRSA isolates among the 12 S. aureus isolated. However, PFGE with 2 different restriction enzymes was more discriminatory for differences among 5 isolates within the MRSA cluster, including the 2 LZD-resistant strains. The LZD-resistant strains had identical SmaI PFGE patterns and similar but not identical EagI PFGE patterns, which were related to but distinguishable from all prior LZD-susceptible isolates. Recent studies have shown that S. aureus isolates that differed by Յ3 bands by PFGE represent clonal variants 8 and that point mutations are responsible for the initial stages of clonal diversification in S. aureus. 9 Most likely, the resistant strain emerged in patient no. 1, who received low LZD doses for an extended period, and was then passed to her sister. Both sisters could have carried the LZD-resistant strains for long periods without causing overt disease, allowing for some clonal diversification in each individual.
Pediatric patients treated with suppressive once-daily doses may be at greater risk of developing LZD resistance because of pharmacokinetic differences from adults. Children less than 12 years old have increased plasma clearance of LZD and a decreased area under the curve of drug concentration. The elimination half-life increases gradually over childhood and reaches adult values in adolescence. 10 Therefore, the recommended dosing regimen is 10 mg/kg every 8 hours for children less than 12 years of age and 10 mg/kg every 12 hours for those 12 years or greater. Our patients received low-dose regimens of only 5 to 9 mg/kg per day and treatment dosages of 22 mg/kg per day for 
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Linezolid-Resistant Staphylococcus aureus patient no. 1 (who was less than 12 years old) and 15 mg/kg per day for patient no. 2. One of the concerns surrounding long-term LZD use is adverse events. Overall, LZD is well-tolerated in pediatric patients with the majority of adverse reactions being diarrhea, nausea/ vomiting, headache, rash and elevated serum transaminases. 11 However, reversible bone marrow toxicity occurs frequently in adult patients treated with LZD for greater than 2 weeks. Although this appears to occur less frequently in pediatric patients, long-term administration experience is limited. Significant differences in bone marrow suppression have not been observed between LZD and vancomycin and cefadroxil in controlled pediatric trials. 12 However, in those studies, the course of antibiotics did not exceed 28 days and bone marrow toxicity often increases with length of therapy. Peripheral and optic neuropathy have been associated with long-term therapy with LZD in adults, occurring at a mean of 6.1 months of therapy in 19 reported cases. 13 Neuropathy has not been reported in pediatric patients, although long-term administration data are limited. There is some suggestion that the neuropathy and/or bone marrow toxicity may be ameliorated with pyridoxine, but further investigation is necessary.
14,15 Our patients were monitored for bone marrow toxicity by frequent blood examinations, which showed no suppression. They had no evidence of neuropathy.
As community and hospital-acquired MRSA continues to increase, there will likely be increased LZD use with associated LZD resistance. This may be more of a problem in immunodeficient patients who require prolonged antibiotic therapy. The development of LZD resistance in these 2 patients suggests that prolonged low-dose LZD therapy can be a risk factor for development of LZD resistance. If suppressive LZD therapy is used, children may need more frequent dosing schedules than adults (such as twice daily instead of once) because of the pharmacokinetic differences between children and adults. Finally, the emergence of LZD-susceptible S. aureus 2 months after discontinuation of LZD therapy in our 2 patients, as well as after 7 months in a previously reported case, 2 suggests that contrary to what has been observed in vitro, 5 bacterial fitness in vivo may be impaired by the G2576U ribosomal mutation. M. africanum is seen in equatorial Africa. M. microti is not pathogenic in humans. M. bovis is rarely reported as a cause of infection in solid organ transplant (SOT) patients. 3 Infection with M. tuberculosis is more common in SOT patients and incidence ranges from 0.5% to 15% depending on the type of transplant and the geographic area where the patient resides. 4 We describe a pediatric case of wild-type M. bovis disease in a renal transplant patient. The purpose of this case report is to review the management issues associated with treatment of M. bovis infections in patients with solid organ transplants receiving immunosuppressive therapy.
CASE REPORT
The patient is an 8-year 4-month-old girl who had a renal transplant 4 years before presentation. The patient was seen in an emergency room with a 1-week history of cough, a 2-day history of chest pain and fever to 101.5°F. She denied shortness of breath, vomiting, diarrhea, abdominal pain, sick contacts or tuberculosis exposure. Her radiograph showed a left lower lobe infiltrate and she was treated with intravenous ceftriaxone. Official report of the radiograph revealed additional bilateral nodules. Azithromycin was added and a purified protein derivative (PPD) with Candida controls was placed before transfer to our institution for further management.
On admission to our institution, the patient had a respiratory rate of 26 breaths/min without distress and oxygen saturation of 97% in room air. Chest auscultation revealed slightly decreased breath
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The Pediatric Infectious Disease Journal • Volume 25, Number 6, June 2006 sounds on the left lateral side. The remaining physical examination was normal. Trimethoprim-sulfamethoxazole were added to the regimen. Computed tomography (CT) of the chest revealed compressive atelectasis in the left lower lobe with a small left pleural effusion, multiple bilateral nodules with ill-defined surrounding inflammation and hemorrhage and a 3.3 ϫ 1-cm cavitary lesion with an air/fluid level but no calcification. The PPD intradermal test was positive with 22.5 mm of induration at 72 hours. The patient's medical history was significant for a cadaveric renal transplant secondary to end-stage renal disease from focal segmental glomerulosclerosis. She received immunosuppressive therapy with 2 mg tacrolimus twice a day and 3 mg prednisolone every morning. Approximately 4 months before presentation, 4 mg sirolimus every day was added to her immunosuppressive regimen.
A PPD intradermal test done 1 year after transplant had no induration. She had never received antituberculosis medications in the past. Except for live vaccines, her immunizations were up to date. She had received Bacille-Calmette Guerin (BCG) vaccine in Mexico when she was 1 month old.
The patient had not recently traveled. Her last major trip was 1 year before the kidney transplant when she visited her extended family in Michoacan, Mexico. Her father's family owns a farm where they raise cattle, pigs and chickens. They boil cow's milk before drinking. The cheese consumed in Mexico was unpasteurized. She had no consumption of unpasteurized cheese in the United States. Her mother and brother were found to have latent tuberculosis infection with a positive PPD and normal chest radiograph and were treated with isoniazid (INH). Her father had a negative PPD.
Cultures of sputum and gastric aspirate specimens were positive for MTB complex. The susceptibility pattern of MTB complex showed resistance to pyrazinamide (PZA) and susceptibility to INH, rifampin (RIF) and ethambutol (ETH), consistent with M. bovis. High-performance liquid chromatography performed at the California Department of Health Services Microbial Diseases Laboratory confirmed that the organism was M. bovis wild-type, not BCG vaccine strain.
Remaining investigations revealed no evidence of EpsteinBarr virus or cytomegalovirus DNA by polymerase chain reaction. She had negative Bartonella species serology, past immunity to Mycoplasma pneumoniae, and a negative urine Legionella antigen. A CT scan of the abdomen and pelvis showed a normal liver, spleen and adrenal glands, a right abdominal ectopic kidney, an atrophic left kidney and no lymphadenopathy or free fluid. An ophthalmology examination was negative for tubercles. Urine culture for acid fact bacilli (AFB) was negative.
The patient was initially treated with INH, PZA, and ETH after the PPD was read as positive. Although RIF was not initially used secondary to concerns of accelerating tacrolimus metabolism and possibly increasing the risk of rejection, it was added 1 month later. The patient's tacrolimus dosage was incrementally increased from 2 mg twice a day to 6 mg twice a day to maintain trough values at a target of 5 to 7 ng/mL. The patient was continued on her usual dosage of prednisolone and sirolimus was discontinued. The patient had no evidence of interim acute rejection episodes and received 15 months of antituberculosis treatment (INH, RIF and ETH for 2 months; INH and RIF for 13 months). The patient is currently doing well and she has not had recurrence of infection after 4 years of follow up off therapy.
DISCUSSION
Robert Koch first isolated M. bovis in 1882 from cattle and humans. 5 Several years later, a British Royal Commission definitively concluded that the bovine tubercle bacillus was a health hazard to humans. 6 Humans usually acquire M. bovis from cattle by ingesting contaminated dairy products, from inhalation of aerosol from infected cattle or carcasses or rarely from other humans. Transmission of bovine tuberculosis from infected cow's milk to children was a major public health problem in the first half of the 20th century. During an epidemic in Sweden in 1936, one cow in a herd that supplied milk to a village had tuberculosis mastitis with large numbers tubercle bacilli in the milk. Ninety percent of children who drank the infected milk tested positive with a tuberculin test compared with only 7% who did not drink the infected milk. 7 Children have a higher risk of becoming infected with M. bovis than adults. In 2 studies from southern California, M. bovis disease in children accounted for approximately one third of culturepositive tuberculosis cases compared with 5% of cases in adults. 8, 9 Unpasteurized dairy products from infected dairy cattle were likely the primary source of infection. 10 Most cases occurred in Hispanic children or in HIV-infected adults. Our patient was most likely exposed to M. bovis through her visits to the family farm in Mexico and from consumption of unpasteurized cheese.
Children infected with M. bovis usually present with cervical lymphadenitis (scrofula) or with infection of the intestinal tract or peritoneum. 2, 11 Pulmonary manifestations of M. bovis disease are less common. 9, 11 In a study from San Diego, two thirds of patients had cervical adenitis or intraabdominal presentations. 8 M. bovis is also likely to cause extrapulmonary tuberculosis in adults. The most common sites of infection are in cervical lymph nodes and skin; lupus vulgaris is a form of chronic skin tuberculosis, which occurs when an infected lymph node ruptures. 11 Before development of antituberculosis medications, approximately one third of children younger than 5 years with M. bovis disease died. 2 Deaths from abdominal tuberculosis in Great Britain decreased from 1107 deaths in 1921 to 12 deaths in 1953 after implementation of pasteurization and infected cattle eradication programs. 12 After the implementation of infected cattle eradication programs and pasteurization of milk, pulmonary and genitourinary manifestations of M. bovis disease paradoxically became more common in Great Britain, [11] [12] [13] presumably from reactivation or late progression of primary disease. However, large numbers of reactivation disease were not observed in children, although many were infected with M. bovis before eradication and pasteurization programs. The reasons for this are unclear. Lower reactivation rates, incomplete identification of the bacteria or underreporting of M. bovis disease may be explanations, especially considering the similar clinical presentations of M. bovis and M. tuberculosis. 9, 12 Lack of "test and slaughter" programs in developing countries make cattle to human transmission of M. bovis likely but probably undocumented as a result of inaccessibility of laboratory techniques to distinguish M. bovis from M. tuberculosis. 14 Prevention of Mycobacterium bovis. Epidemiology data suggests that the most common route of infection with M. bovis is through ingestion, specifically of unpasteurized dairy products from infected cattle. All solid organ transplant patients should be educated to avoid unpasteurized food.
2, both blood and CSF culture grew fully susceptible Neisseria meningitidis, serogroup B. This was subsequently confirmed on both blood and CSF polymerase chain reaction for meningococcal DNA. On day 3, the child was noted to be unable to visually fix and follow objects. Ophthalmology assessment revealed a right gaze palsy, normal pupillary responses and normal fundi. Computed tomography scan demonstrated bilateral parietooccipital infarcts. He received 10 days of intravenous ceftriaxone and was discharged home after 11 days. His visual loss persisted at discharge but hearing was normal and there were no other focal neurologic abnormalities. At 6-month follow up, he was reacting to a bright light but was not fixing or following. The gaze palsy had resolved and fundoscopy was normal. The final diagnosis was cortical blindness with preservation of light response. DISCUSSION Cerebral infarction is an uncommon but recognized complication of meningococcal meningitis. There are several reports in the literature of cerebral or cerebellar infarction complicating bacterial meningitis, [2] [3] [4] [5] [6] Infarction of the basal ganglia and caudate, presenting with hemiparesis and cranial nerve deficits, 7 and spinal cord infarction 8, 9 have been described as complications of meningococcal meningitis in adults but parieto-occipital infarction in childhood meningococcal meningitis has not previously been reported. Persistent visual loss in addition to other neurologic sequelae is also a recognized complication of bacterial meningitis, but this case is unusual in that the persistent visual loss was the sole neurologic complication of meningococcal meningitis.
In the case reported here, the observation of visual loss on day 3 and the bilateral distribution could be consistent with vasculitis as the underlying cause. The child did not have any signs of shock and was not hypotensive at any time, thereby making infarction secondary to cerebral hypoperfusion unlikely.
The pathophysiology of neuronal injury associated with bacterial meningitis involves several mechanisms: 1) raised intracranial pressure secondary to cytotoxic edema and increased vascular permeability with secondary ischemia, 2) leukocyte extravasation into the subarachnoid space, 3) cerebral ischemia secondary to reduced cerebral perfusion pressure or vasculitis and 4) direct toxic effect on neurons from reactive oxygen intermediates, caspases and proteases. 7 The use of steroids as adjunctive therapy in bacterial meningitis is controversial. A large multicenter trial in adults in Europe showed an improved outcome with adjunctive therapy, 10 but another large trial involving children in sub-Saharan Africa demonstrated no benefit. 11 Dexamethasone, by virtue of its anti-inflammatory effects, might be expected to reduce neuronal injury as a result of inflammation in the subarachnoid space and also injury secondary to vasculitis. It is impossible to say whether commencing adjunctive steroids in this child on day 3 might have made any difference to the persistent visual loss. bial susceptibility.
